Japan draws up nephropathy diagnoses guidelines:
This article was originally published in Clinica
An expert group in Japan has begun drawing up guidelines for the diagnosis and treatment of diabetic nephropathy. This follows the discovery that there are wide variations across the country in the interpretation of microalbuminuria test results. The group plans to establish standard ranges for urine microalbumin, register all patients in Japan with diabetic nephropathy and undertake a five-year follow-up patient study, reports Pharma Japan.
You may also be interested in...
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.